eligibility_summary
Adults ≥18, ECOG ≤2, FL grade 1–3a (no active DLBCL/3b), relapsed/refractory after ≥1 line, CD20+, active/measurable disease, adequate marrow/organ function, recovered from prior therapy, biopsy available, contraception. Exclude prior mosunetuzumab/polatuzumab (>2 doses), recent SCT/CAR‑T/chemo/RT/live vaccine/immunosuppression, significant infections, CNS disease, ≥grade 2 neuropathy, major autoimmune/cardiac/pulmonary disease, pregnancy, recent surgery, other active cancers.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm trial in relapsed/refractory grade 1–3a follicular lymphoma testing: 1) Mosunetuzumab (Lunsumio), a subcutaneous bispecific T‑cell–engaging monoclonal antibody (biologic) that binds CD20 on B cells and CD3 on T cells, recruiting and activating cytotoxic T cells to kill malignant B cells. 2) Polatuzumab vedotin (Polivy), an intravenous antibody‑drug conjugate (ADC) targeting CD79b on B cells that delivers the microtubule inhibitor MMAE, causing cell cycle arrest and apoptosis. Targets/pathways: CD20+ and CD79b+ follicular lymphoma B cells, T‑cell activation via CD3 with immune synapse formation and perforin/granzyme‑mediated cytotoxicity, ADC internalization with microtubule disruption. Exploratory aims assess biomarkers and CD20 mutation/downregulation at relapse. Tocilizumab may be used to manage cytokine release syndrome.